For POET Technologies, $400M in New Cash Can’t Mask a Doubled Quarterly Loss

POET raises $400M for photonic chip scaling but Q1 loss doubled to $12.34M. Stock volatile with 45% crash, 20% short interest, class-action suit. Market split.

POET Technologies finds itself in an unusual tug-of-war. The company just banked $400 million to scale up its photonic chip manufacturing, yet its latest quarterly loss came in twice as steep as analysts had forecast. The stock, which has seesawed violently in recent weeks, now appears to be settling into a holding pattern as the market weighs two very different stories.

First-quarter results revealed a revenue surprise that was quickly overshadowed. Sales hit $503,389, a 202% jump from the prior-year quarter and well above the $250,000 consensus estimate. But the bottom line told a harsher tale: a net loss of $12.34 million, or $0.08 per share, compared with a consensus forecast of just $0.04 per share in red ink. The earnings miss sent shares sliding 7.7% on the day after the release, closing at $13.46, with an intraday dip to $13.27.

The capital injection that closed on May 18 offers a counter-narrative. POET placed roughly 19 million shares along with warrants to a single institutional investor, raising $400 million earmarked for production ramp-up. The company has already expanded its Singapore lab to nearly three times its previous footprint and now controls about 1,900 square meters of assembly space in Malaysia. Management insists the funds are going straight into scaling output, not just shoring up the balance sheet.

That cash is badly needed to back the pipeline POET has built. The company is developing optical engines, light sources and high-speed modules for AI data centers, and has sealed a collaboration with LITEON, a joint 1.6T transceiver module project with Lessengers, and a $50 million supply agreement with Lumilens. The Lumilens deal includes options for over 22 million shares at $8.25 each over nine years, a structure that both excites retail traders and alarms skeptics.

The market’s split is unusually sharp. Jim Cramer has voiced caution, pointing to execution risks and the company’s history of dilution as reasons to stay on the sidelines until POET shows more stability. Reddit forums, by contrast, are buzzing about the Lumilens contract and Malaysia’s production capacity as the catalysts for a turnaround. Short sellers, meanwhile, are circling: the short interest stands at about 20% of the float, and most analysts rate the stock a sell with price targets around $8.00.

The volatility that has defined POET this quarter shows no sign of easing. On April 27 the stock cratered 45% in a single session after reports surfaced that Marvell Technology had canceled all orders for Celestial AI—a client POET was indirectly tied to. That was followed by a string of double-digit swings: up 43% on May 14, down 22% the next day, down 11% on May 18, then up 13% on May 20. The current consolidation around $13.26 is the calmest stretch in weeks, but the shares remain roughly 9% below their May 22 close of $14.59 and even further from the May 15 peak of $15.97.

Legal headwinds add another layer of uncertainty. A class-action lawsuit has been filed, with a lead-plaintiff deadline of June 29, 2026. The allegations center on company statements made during the April crash. For now, the story hinges on whether POET can convert its optical engine pipeline for 800G and 1.6T applications into concrete customer orders and production volume. The $400 million gives it the means; the next few quarters will show whether the market’s faith is justified.